Newborn Screening and Genetic Analysis Identify Six Novel Genetic Variants for Primary Carnitine Deficiency in Ningbo Area, China

Primary carnitine deficiency (PCD) is an autosomal recessive disorder that could result in sudden death. It is caused by a defect in the carnitine transporter encoded by SLC22A5 (Solute Carrier Family 22 Member 5, MIM:603377). Currently, a number of variants in SLC22A5 have been identified, however, the PCD prevalence and its variants in Ningbo area are unclear. In this study, we screened 265,524 newborns by using tandem mass spectrometry. Variants in SLC22A5 were further detected by next-generation sequencing in individuals with abnormal free carnitine levels (C0). We identified 53 newborns with abnormal C0 levels and 26 with variants in SLC22A5. Among them, 16 with compound heterozygous or homozygous variants in SLC22A5 were diagnosed with PCD, suggesting the PCD birth prevalence in Ningbo city was 1/16,595. Moreover, the C0 level was significantly (P = 0.013) higher in PCD patients than in those with one variant. Besides, the c.1400C > G (p. S467C) and c.51C > G (p. F17L) variants were the most frequent and six novel variants are all predicted to be damaging. This study reports the largest PCD patients in Ningbo area by newborn screening and expands the variant spectrum of SLC22A5. Our findings demonstrate the clinical value of combining NBS program results with DNA analysis for the diagnosis of PCD.

[1]  Ting Zhang,et al.  Screening 3.4 million newborns for primary carnitine deficiency in Zhejiang Province, China. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[2]  Hong Li,et al.  Expanded Newborn Screening for Inborn Errors of Metabolism by Tandem Mass Spectrometry in Suzhou, China: Disease Spectrum, Prevalence, Genetic Characteristics in a Chinese Population , 2019, Front. Genet..

[3]  Alexandros Kouris,et al.  VarSome: the human genomic variant search engine , 2018, bioRxiv.

[4]  Dong Hwan Lee,et al.  Diversity in the incidence and spectrum of organic acidemias, fatty acid oxidation disorders, and amino acid disorders in Asian countries: Selective screening vs. expanded newborn screening , 2018, Molecular genetics and metabolism reports.

[5]  Zhengyan Zhao,et al.  [Screening for fatty acid oxidation disorders of newborns in Zhejiang province:prevalence, outcome and follow-up]. , 2017, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[6]  N. Lahrouchi,et al.  Exome sequencing identifies primary carnitine deficiency in a family with cardiomyopathy and sudden death , 2017, European Journal of Human Genetics.

[7]  N. Longo,et al.  Carnitine transport and fatty acid oxidation. , 2016, Biochimica et biophysica acta.

[8]  John J. Mitchell,et al.  The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study , 2016, Orphanet Journal of Rare Diseases.

[9]  J. Loeber,et al.  Current status of newborn screening worldwide: 2015. , 2015, Seminars in perinatology.

[10]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[11]  Philippe M. Campeau,et al.  Genotype-Phenotype Correlation , 2014 .

[12]  A. El-Hattab,et al.  Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management , 2012, Orphanet Journal of Rare Diseases.

[13]  K. Rascati,et al.  Cost-effectiveness of expanded newborn screening in Texas. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Joshua L. Deignan,et al.  Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California. , 2012, Molecular genetics and metabolism.

[15]  N. Longo,et al.  Genotype–phenotype correlation in primary carnitine deficiency , 2012, Human mutation.

[16]  Zhengyan Zhao,et al.  [Screening for neonatal inborn errors of metabolism by electrospray ionization-tandem mass spectrometry and follow-up]. , 2011, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[17]  M. Leichsenring,et al.  Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany * , 2011, Orphanet journal of rare diseases.

[18]  R. Boles,et al.  Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143 subjects evaluated for systemic carnitine deficiency , 2010, Human mutation.

[19]  J. Dhondt.  Expanded newborn screening: social and ethical issues , 2010, Journal of Inherited Metabolic Disease.

[20]  N. Longo,et al.  Disorders of carnitine transport and the carnitine cycle , 2006, American journal of medical genetics. Part C, Seminars in medical genetics.

[21]  T. Cowan,et al.  A missense mutation in the OCTN2 gene associated with residual carnitine transport activity , 2000, Human mutation.

[22]  B. Wilcken,et al.  Newborn screening with tandem mass spectrometry: 12 months' experience in NSW Australia , 1999, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[23]  T. Coşkun,et al.  Identification of mutations and evaluation of cardiomyopathy in Turkish patients with primary carnitine deficiency. , 2012, JIMD reports.

[24]  D. Webster.  Newborn screening in Australia and New Zealand. , 2003, The Southeast Asian journal of tropical medicine and public health.

[25]  G. Tsujimoto,et al.  Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter , 1999, Nature Genetics.